217 related articles for article (PubMed ID: 22128608)
1. [From myocardium to the atherosclerotic plaque: new perspectives in cardiologic imaging].
Gargiulo P; D'Amore C; Dellegrottaglie S; Leosco D; Rengo G; Musella F; Pirozzi E; Mosca S; Casaretti L; Formisano R; Bologna A; Parente A; Conte S; Perrone-Filardi P
Monaldi Arch Chest Dis; 2011 Jun; 76(2):60-5. PubMed ID: 22128608
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive molecular imaging of vulnerable atherosclerotic plaques.
Magnoni M; Ammirati E; Camici PG
J Cardiol; 2015 Apr; 65(4):261-9. PubMed ID: 25702846
[TBL] [Abstract][Full Text] [Related]
3. Histological validation of iron-oxide and gadolinium based MRI contrast agents in experimental atherosclerosis: the do's and don't's.
den Adel B; Bovens SM; te Boekhorst B; Strijkers GJ; Poelmann RE; van der Weerd L; Pasterkamp G
Atherosclerosis; 2012 Dec; 225(2):274-80. PubMed ID: 22882907
[TBL] [Abstract][Full Text] [Related]
4. Varying correlation between 18F-fluorodeoxyglucose positron emission tomography and dynamic contrast-enhanced MRI in carotid atherosclerosis: implications for plaque inflammation.
Wang J; Liu H; Sun J; Xue H; Xie L; Yu S; Liang C; Han X; Guan Z; Wei L; Yuan C; Zhao X; Chen H
Stroke; 2014 Jun; 45(6):1842-5. PubMed ID: 24788973
[TBL] [Abstract][Full Text] [Related]
5. [Iron-oxide-enhanced MR imaging of inflammatory atherosclerotic lesions: overview of experimental and initial clinical results].
Schmitz SA
Rofo; 2003 Apr; 175(4):469-76. PubMed ID: 12677500
[TBL] [Abstract][Full Text] [Related]
6. Advances in noninvasive imaging for evaluating clinical risk and guiding therapy in carotid atherosclerosis.
Degnan AJ; Young VE; Gillard JH
Expert Rev Cardiovasc Ther; 2012 Jan; 10(1):37-53. PubMed ID: 22149525
[TBL] [Abstract][Full Text] [Related]
7. Iron Oxide Nanoparticles as Contrast Agents in Molecular Magnetic Resonance Imaging: Do They Open New Perspectives in Cardiovascular Imaging?
Ploussi AG; Gazouli M; Stathis G; Kelekis NL; Efstathopoulos EP
Cardiol Rev; 2015; 23(5):229-35. PubMed ID: 25688663
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET imaging of atherosclerosis: Do we know what we see?
Sheikine Y; Akram K
Atherosclerosis; 2010 Aug; 211(2):371-80. PubMed ID: 20202637
[TBL] [Abstract][Full Text] [Related]
9. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives.
Burtea C; Ballet S; Laurent S; Rousseaux O; Dencausse A; Gonzalez W; Port M; Corot C; Vander Elst L; Muller RN
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):e36-48. PubMed ID: 22516067
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging of atherosclerosis in translational medicine.
Perrone-Filardi P; Dellegrottaglie S; Rudd JH; Costanzo P; Marciano C; Vassallo E; Marsico F; Ruggiero D; Petretta MP; Chiariello M; Cuocolo A
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):969-75. PubMed ID: 21174089
[TBL] [Abstract][Full Text] [Related]
11. Imaging atherosclerosis in HIV: carotid intima-media thickness and beyond.
Longenecker CT; Hoit BD
Transl Res; 2012 Mar; 159(3):127-39. PubMed ID: 22340762
[TBL] [Abstract][Full Text] [Related]
12. Review of cardiovascular imaging in the journal of nuclear cardiology in 2015. Part 1 of 2: Plaque imaging, positron emission tomography, computed tomography, and magnetic resonance.
AlJaroudi WA; Hage FG
J Nucl Cardiol; 2016 Feb; 23(1):122-30. PubMed ID: 26542991
[TBL] [Abstract][Full Text] [Related]
13. Target identification for the diagnosis and intervention of vulnerable atherosclerotic plaques beyond
Bucerius J; Dijkgraaf I; Mottaghy FM; Schurgers LJ
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):251-265. PubMed ID: 30302506
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging of the atherosclerotic plaque using positron emission tomography.
Toor IS; Dweck MR; Newby DE
J R Coll Physicians Edinb; 2014; 44(2):139-45. PubMed ID: 24999778
[TBL] [Abstract][Full Text] [Related]
15. [The progress of nuclear medicine and magnetic resonance molecular imaging of atherosclerotic vulnerable plaques].
Zhao ZM; Qin SC
Sheng Li Ke Xue Jin Zhan; 2011 Apr; 42(2):86-90. PubMed ID: 21770253
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
Fayad ZA; Mani V; Woodward M; Kallend D; Bansilal S; Pozza J; Burgess T; Fuster V; Rudd JH; Tawakol A; Farkouh ME
Am Heart J; 2011 Aug; 162(2):214-221.e2. PubMed ID: 21835280
[TBL] [Abstract][Full Text] [Related]
17. Complementary value of cardiac FDG PET and CT for the characterization of atherosclerotic disease.
Stolzmann P; Subramanian S; Abdelbaky A; Maurovich-Horvat P; Scheffel H; Tawakol A; Hoffmann U
Radiographics; 2011; 31(5):1255-69. PubMed ID: 21918043
[TBL] [Abstract][Full Text] [Related]
18. Nuclear Imaging: Focus on Vascular Probes.
Hyafil F; Vigne J
Arterioscler Thromb Vasc Biol; 2019 Jul; 39(7):1369-1378. PubMed ID: 31242032
[TBL] [Abstract][Full Text] [Related]
19. Current techniques for MR imaging of atherosclerosis.
Balu N; Wang J; Dong L; Baluyot F; Chen H; Yuan C
Top Magn Reson Imaging; 2009 Aug; 20(4):203-15. PubMed ID: 20805731
[TBL] [Abstract][Full Text] [Related]
20. Validity of dual MRI and F-FDG PET imaging in predicting vulnerable and inflamed carotid plaque.
Saito H; Kuroda S; Hirata K; Magota K; Shiga T; Tamaki N; Yoshida D; Terae S; Nakayama N; Houkin K
Cerebrovasc Dis; 2013; 35(4):370-7. PubMed ID: 23635390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
